W.L. Fodor
William L. Fodor, PhD
Director, Translational Sciences
Dr. William "Bill" Fodor is Director, Translational Sciences at the Cell Therapy Group.
Bill has over 20 years of research, management and training experience in both academia and the biotechnology industry. An experience leader and team builder, Dr. Fodor has a proven track record of developing novel genetically engineered cells, both stem cells and differentiated cells, genetically engineered tissues and organs designed for regenerative medicine applications.
Dr. Fodor’s experience as an Associate Professor, as a member of Executive Management Teams in the biotechnology industry, with grant and venture capital fund raising efforts, as well as participation in business development activities has gained Dr Fodor a broad range of core competencies in multiple areas including:
Dr. Fodor is currently acting as the Chief Science Officer for GlyGenix Therapeutics, Inc., a small start-up biotechnology company focused on metabolic disorders. He is also the founder of bio*Logic, LLC, a biotechnology consulting service that currently has clients in a variety of scientific areas, including gene therapy, stem cells, RNAi applications, tools for stem cell biology as well as oversight of academic collaborative research efforts.
Previously, Dr. Fodor was Senior Director of Product Development for ViaCell, Inc., where he oversaw basic stem cell research, the hematopoietic stem cell Process Development Group and the stem cell Clinical Manufacturing Team. Prior to joining ViaCell, Dr. Fodor was an Associate Professor at the University of Connecticut in the Center for Regenerative Biology and the Department of Molecular Cell Biology, where he taught genetics and conducted research in stem cell engineering, transgenic animal production, cell replacement therapies for diabetes and transplant immune rejection. Dr. Fodor initiated his professional career as a founding scientist at Alexion Pharmaceuticals where he directed the transgenic animal program focused on cell and tissue engineering for regenerative medicine applications and through his efforts earned a position on the Executive Management Team.
Bill has authored over 45 peer reviewed journal articles, book chapters, and opinion papers. He has been an invited speaker at multiple domestic and international scientific meetings. Dr. Fodor received a B.S. degree from the Department of Genetics and a Ph.D. in Molecular Genetics from Ohio State University. His post-doctoral training included molecular immunology research at Biogen and at the Yale School of Medicine Immunobiology Department.
Director, Translational Sciences
Dr. William "Bill" Fodor is Director, Translational Sciences at the Cell Therapy Group.
Bill has over 20 years of research, management and training experience in both academia and the biotechnology industry. An experience leader and team builder, Dr. Fodor has a proven track record of developing novel genetically engineered cells, both stem cells and differentiated cells, genetically engineered tissues and organs designed for regenerative medicine applications. Dr. Fodor’s experience as an Associate Professor, as a member of Executive Management Teams in the biotechnology industry, with grant and venture capital fund raising efforts, as well as participation in business development activities has gained Dr Fodor a broad range of core competencies in multiple areas including:
• Executive Management (team building, cross functional team development, budget management and organizational alignment)Bill possesses keen creativity and excellent problem solving skills, with an ability to evaluate data and to trouble shoot scientific road blocks. His broad experience within the regenerative medicine field spans many scientific disciplines, including immune responses to transplanted cells, neural repair, stem cell applications for cardiac repair, cartilage and bone tissue engineering, whole organ transplantation, and genetic engineering of recombinant molecules. Bill’s thorough understanding of regenerative medicine, cell therapy, tissue engineering, molecular biology, manufacturing and translational product development, provides his clients with a unique combination of technical and development skills that can be directed at all aspects of the biotechnology business.
• Basic Research (cell and tissue engineering, cell, tissue and organ transplantation, stem cell biology, large and small animal transgenic engineering, novel bi-functional molecule engineering, immunology, molecular biology and genetics)
• Translational Research (design and implementation of PoC pre-clinical animal models, biomarker assays, IND preparation)
• Process Development (bench scale bioreactor process optimization, stem cell expansion & differentiation, RNAi screening, recombinant protein production and purification)
• Clinical Manufacturing (cGMP training, SOPs, batch records, large-scale cell culture, cryopreservation, product specifications)
• Project Management (project design & implementation, budget alignment, strategic planning)
• Management of External Collaborations (corporate, academic)
Dr. Fodor is currently acting as the Chief Science Officer for GlyGenix Therapeutics, Inc., a small start-up biotechnology company focused on metabolic disorders. He is also the founder of bio*Logic, LLC, a biotechnology consulting service that currently has clients in a variety of scientific areas, including gene therapy, stem cells, RNAi applications, tools for stem cell biology as well as oversight of academic collaborative research efforts.
Previously, Dr. Fodor was Senior Director of Product Development for ViaCell, Inc., where he oversaw basic stem cell research, the hematopoietic stem cell Process Development Group and the stem cell Clinical Manufacturing Team. Prior to joining ViaCell, Dr. Fodor was an Associate Professor at the University of Connecticut in the Center for Regenerative Biology and the Department of Molecular Cell Biology, where he taught genetics and conducted research in stem cell engineering, transgenic animal production, cell replacement therapies for diabetes and transplant immune rejection. Dr. Fodor initiated his professional career as a founding scientist at Alexion Pharmaceuticals where he directed the transgenic animal program focused on cell and tissue engineering for regenerative medicine applications and through his efforts earned a position on the Executive Management Team.
Bill has authored over 45 peer reviewed journal articles, book chapters, and opinion papers. He has been an invited speaker at multiple domestic and international scientific meetings. Dr. Fodor received a B.S. degree from the Department of Genetics and a Ph.D. in Molecular Genetics from Ohio State University. His post-doctoral training included molecular immunology research at Biogen and at the Yale School of Medicine Immunobiology Department.